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T he majority (about 65%) of nonmetastatic breast cancer survivors are prescribed adjuvant endocrine therapy (AET) with agents such as estrogen receptor agonists/antagonists and/or aromatase inhibitors 
(Burstein et al., 2010). AET is a long-term therapy 
currently administered for five years, although an up-
dated American Society of Clinical Oncology guideline, 
reflecting emerging data, recommended that women 
completing five years of adjuvant tamoxifen should 
be offered continuation of AET for a total of 10 years 
to further improve morbidity and mortality outcomes 
(Burstein et al., 2014; Davies et al., 2012). 
Patients with breast cancer receiving any kind of 
AET may experience multiple, persistent symptoms, 
including vasomotor symptoms, sexual dysfunction, 
insomnia, fatigue, anxiety, depression, and arthralgias 
(Amir, Seruga, Niraula, Carlsson, & Ocana, 2011; 
Burstein et al., 2010; Cella et al., 2006; Fontein et al., 
2013; Hickey et al., 2008; Rechis et al., 2010; Stearns & 
Hayes, 2002; van Londen et al., 2013). These symptoms 
negatively affect survivors’ functional status and qual-
ity of life (Cella et al., 2006; Conde et al., 2005; Ganz, 
Rowland, Desmond, Meyerowitz, & Wyatt, 1998; 
Gupta et al., 2006; Land et al., 2006; Perry, Kowalski, & 
Chang, 2007; Stein, Jacobsen, Hann, Greenberg, & Ly-
man, 2000; Wilson & Cleary, 1995). Negative symptom 
experiences reported in the clinical literature appear 
to contribute to lack of adherence to AET (Bender et 
al., 2014; Cluze et al., 2011; Fink, Gurwitz, Rakowski, 
Guadagnoli, & Silliman, 2004; Henry et al., 2012; Her-
shman et al., 2010; Murphy, Bartholomew, Carpentier, 
Bluethmann, & Vernon, 2012), which, in turn, has been 
linked to higher mortality (Hershman et al., 2011). To 
date, however, little patient-oriented research has fo-
cused on experiences of AET-related symptoms, how 
patients with breast cancer try to manage symptoms, 
or how these experiences influence patients’ decision 
making regarding AET continuation. This focus on 
symptom experience may be particularly relevant for 
those aged 50 years and older who are already at risk 
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for menopausal symptoms (Blumel et al., 2000; Che-
draui, San Miguel, & Avila, 2009; Schwarz et al., 2007), 
comorbidities (Baumeister, Balke, & Harter, 2005), and/
or effects of normal aging (Motl & McAuley, 2010; van 
Londen et al., 2013). 
The purpose of this focus group study was to explore 
survivors’ recollection of the conversation with the 
medical oncologist about starting AET, experiences with 
AET-related symptoms, AET-related symptom manage-
ment, challenges to taking AET, and views about how 
AET-related symptoms might be better managed. 
Methods
A focus group design was used to foster dynamic 
discussion and gain formative insight into patient 
experiences (Patton, 2002). The size of each group was 
intentionally small (3–4) to maximize individual input 
(Hagan & Donovan, 2013). Female breast cancer sur-
vivors who met the following eligibility criteria were 
invited to participate in the study: (a) aged 50 years or 
older, (b) self-reported to have been undergoing AET 
for longer than one year (to limit the confounding 
influence of chemotherapy-related symptoms), and 
(c) experiencing at least one moderately distressing 
symptom, as assessed by the Breast Cancer Prevention 
Trial (BCPT) symptom scale, a validated measure of 
physical symptoms in breast cancer survivors (Stanton, 
Bernaards, & Ganz, 2005). Patients rated symptoms on 
a Likert-type scale of not at all (0), slightly (1), mod-
erately (2), quite a bit (3), and extremely (4). Women 
taking endocrine therapy as part of treatment for meta-
static disease were excluded as this study focused on 
the perspectives of women taking AET to prevent re-
currence. Because cancer stage might affect the AET ex-
perience (Aiello Bowles et al., 2012), women of similar 
severity of illness (based on self-reported lymph node 
status) were included within groups. Additional focus 
groups were conducted until no new themes emerged. 
A total of four focus groups were conducted (two 
lymph node–negative and two lymph node–positive). 
High levels of participation by women in each group 
and similar findings across the lymph node–positive 
and –negative groups increased the authors’ confidence 
to end the study after the fourth focus group (Kuzel, 
1992; Morse, 2000). 
Procedures
The University of Pittsburgh’s Institutional Review 
Board approved the study. Women were recruited 
from outpatient clinics of the University of Pittsburgh 
Medical Center. All focus groups were held at the 
nearby university campus from May to September 2011. 
Recruitment of study participants occurred through 
advertisements in medical oncology practices, research 
registries, and word of mouth. Potentially eligible 
participants were screened by phone and, if eligible, 
mailed a consent form, directions, a short demographic 
survey, and the BCPT symptom scale (Stanton et al., 
2005). Prior to conducting the focus group, the investi-
gator introduced the purpose and process of the study, 
reviewed and signed consent forms, and collected 
completed, self-reported surveys. All participants 
received parking reimbursement, a $20 gift card, and 
refreshments. 
Each focus group was facilitated by a member of the 
study team and also attended by a third investigator. 
The 90-minute sessions were audio recorded and de-
leted following transcription and review. 
Measures
A semistructured interview guide was developed for 
the study that included a series of discussion prompts 
that addressed survivors’ recollection of the conver-
sation with their medical oncologist about starting 
AET, experiences related to successfully taking AET as 
prescribed, experiences with AET-related symptoms, 
AET-related symptom management, and views about 
how AET-related symptoms might be better managed. 
See Table 1 for examples of discussion prompts.
Analysis
Analysis of each focus group’s transcripts was carried 
out in two phases (Patton, 2002; Ryan & Bernard, 2003). 
Initial coding was done by pairs of team members using 
an a priori coding scheme based on the questions in the 
semistructured interview guide. Each pair included the 
first author of this article and one of three team mem-
bers with qualitative data methods expertise (Strauss 
& Corbin, 1990). Two of the authors then individually 
reviewed the coded text and themes (the essence of the 
phenomena or aspects of the text that provide meaning 
to the phenomena) and subthemes (more concrete units 
of information) were extracted, discussed, and agreed 
on using an iterative process (Morse, 2008). No differ-
ences in themes or subthemes were identified between 
the lymph node–positive and –negative focus groups; 
therefore, results are presented together.
Results
A total of 14 female breast cancer survivors partici-
pated in the focus groups. Demographic and clinical 
information for study participants is included in Table 
2. Five themes emerged: (a) initially, taking AET was 
not viewed as a choice to be made but rather a next 
necessary step in curative treatment; (b) after starting 
AET, women experienced unanticipated symptoms; 
(c) during AET, women faced difficulties in making 
sense of and managing their symptoms; (d) frustration 
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in managing symptoms; and (e) over time, women 
became aware that taking AET is a choice and began 
weighing the pros and cons of continued treatment. 
Theme	1:	Adjuvant	Endocrine	Therapy	 
as	a	Necessary	Treatment
At the time of being prescribed AET, breast cancer 
survivors often did not feel they had a real choice; they 
viewed AET as the next necessary step in treatment to 
avoid breast cancer recurrence and death. They did not 
inquire much about AET-related risks or, if they did, 
they felt like the risks were not central to the discussion. 
It shocks me because I felt the fear of God in me. I 
had to take this. I didn’t ask the questions, which 
is so unusual for me.
I don’t think it was really explained to me, all the 
things that might happen. I don’t remember. I’ll be 
honest with you; I really don’t remember. Maybe 
he did tell me everything, but I also knew I wanted 
to live. I didn’t want to take a chance on not doing 
what the doctor told me not to do. 
Theme	2:	Experiencing	Unanticipated	
Symptoms
Survivors talked about being surprised by the wide 
range of symptoms, including vasomotor symptoms, 
sexual dysfunction, insomnia, fatigue, cognitive dys-
function, pain, functional limitations, mood distur-
bance, and anxiety. More importantly, women talked 
about the negative effect of symptoms on their lives. 
I am more forgetful. I work harder at work to do 
the same job that I used to just do. It’s harder for 
me to stay focused, to concentrate, to think clearly, 
to remember everything. 
Because of the side effects and my hands. I’m an 
artist. I’m a floral designer. I couldn’t . . . I still can’t 
pick up a straight pin. I can’t pick up anything 
small like a needle. 
I didn’t expect the night sweats to be so bad. I 
didn’t expect them to interfere with my sleep.
I wouldn’t have ever thought that it would interfere 
so much that I don’t feel like myself. I don’t have 
the energy. I can’t sleep. I’m having trouble at work.
Theme	3:	Difficulty	Making	Sense	 
of	Symptoms
Women talked about a wide range of issues that af-
fected their ability to understand or make sense of their 
symptoms. Three subthemes were identified. 
Uncertainty in determining the cause of their symp-
toms: Women talked about the frustration and worry 
that came from not being able to determine whether 
symptoms were caused by AET, aging, comorbidities, 
or cancer recurrence.
I think it’s so hard to know what is causing what 
and, like I said, if you didn’t have that, other 
things factor in, age and all that, but I do think the 
medications, like you say [referring to comment by 
another participant], exacerbated.
And if you do get aches in your joints, I mean, you get 
scared, you know? What is going on with my body?
Lack of understanding by friends and family: 
Survivors mentioned their frustration when trying to 
Table	1.	Focus	Group	Discussion	Topics	and	Examples	of	Discussion	Prompts
Topic Discussion	Prompt
Understanding of rationale for hormonal 
therapy (recollection of the conversation with 
their medical oncologist about starting AET)
•	 We’d like to start with asking women about their perspectives on why they are taking 
hormonal therapy.
•	 How well do you feel like you understand the benefits and risks of treatment?
Experiences related to consistently taking 
AET as prescribed
•	 What has made it challenging to successfully and consistently take your adjuvant hor-
monal treatment?
•	 Have you ever considered adjusting the therapy yourself or stopping therapy?
Experiences with AET-related symptoms •	 What sorts of side effects or symptoms have you experienced related to your adjuvant 
hormonal treatment?
AET-related symptom management •	 What sorts of things have you tried to control your symptoms related to your treatment?
•	 How well have they worked? 
•	 What challenges did you face in managing your symptoms?
Views about how AET-related symptoms 
might be better managed
•	 What is the one thing that could be done to help women successfully and consistently 
take their hormonal treatment? We are looking for answers that can really be acted on, 
things that could improve the care women receive or other ways that you think women 
could be best supported.
AET—adjuvant endocrine therapy
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talk with others about symptoms. Friends and family 
members who had not experienced cancer were not 
always able to relate or understand. 
You really can only go so far with even your hus-
band. They only want to hear what’s going on for 
a couple of minutes.
Well your friends and relatives don’t want to hear 
about [the symptoms].
Concern that talking about symptoms was seen as 
a sign of emotional or psychological problems by 
providers: Women discussed extensively about diffi-
culty in talking with their providers about symptoms. 
Providers’ responses made them feel like they were 
either overreacting or that the symptoms were a result 
of psychological or emotional problems. 
So then I think, well, am I being a hypochondriac? 
You know, you go home, and it’s like, well, should 
I call another doctor? He seemed like everything’s 
fine. If it was really serious, he would say so.
I would rather have somebody tell me that they 
don’t know why I had a reaction to this or that, 
rather than just make me feel like I’m a child or 
it’s just your hormones or it’s just your mental 
incapacity.
I cried, I lost it, and then right away, he wants me to 
go see the psychiatrist! I don’t need a psychiatrist 
or psychologist.
Theme	4:	Frustration	in	Managing	Symptoms
Survivors often expressed a great deal of frustration 
when talking about their attempts to manage symp-
toms. The following subthemes were identified. 
Dissatisfaction with symptom management infor-
mation from healthcare providers: Women felt like 
no one provider had the time for, expertise in, and/or 
interest in helping them to manage symptoms. 
[The gynecologist] doesn’t do anything but her 
thing. I don’t think she would answer my ques-
tions. Or, even if she did it, you know, would be 
a brush off kind of thing. She doesn’t spend that 
much time with her patients. I don’t think they 
know about the drugs. 
[The providers] just go by what they read in a 
book. . . . I learn more from people who have been 
through it.
Responsible for own symptom management: Sev-
eral women reported that they felt like they needed to 
identify symptom management approaches on their 
own. They reported spending a lot of time reading 
about different strategies and interacting with other 
survivors to get advice. 
When you first started to develop the side effects,  
[the doctor] would tell you things that you would 
try to do to just sort of get over, or get through, or 
alleviate some of them. When they didn’t work, then 
you sort of figured it out on your own. 
I spend hours and hours researching. 
To have these symptoms and at some point you feel 
like there’s no one to talk to outside of other people 
who are going through it or have been through it.
Few effective and tolerable symptom management 
strategies: Women reported that they came to realize 
that few effective symptom management strategies 
Table	2.	Sample	Characteristics	(N	=	14)
Characteristic
—
X     SD
Age (years) 58.8 6.7
Time since breast cancer diagnosis (months) 35 20
Time (months) since AET initiation  28.3 17.9
Percentage of AET-related symptoms rated 
2 or higher 
44.6 17.2
Most bothersome symptoms as rated on the 
BCPT symptom scale
•	 General aches 2.9 0.7
•	 Joint pains 2.9 1
•	 Muscle stiffness 2.7 1.1
•	 Lack of interest in sex 2.5 1.6
•	 Hot flashes 2.3 0.9
Characteristic n
Race
 Caucasian 14
Marital status 
 Married 11
Occupational status 
Employed 4
Not working (retired, disabled, not able 
to find a job)
10
Self-reported lymph node status
 Negative 8
 Positive 6
Cancer treatmenta 
 Mastectomy 6
 Lumpectomy 8
 Radiation therapy 13
 Chemotherapy 9
 HER2/neu receptor antibody 2
AET type 
 Aromatase inhibitor 12
 Tamoxifen 1
 Unknown 1
Adjustment of AET 5
Reasons for AET adjustment 
Menopausal transition (eligible for tamoxifen  
to aromatase inhibitor conversion)
2
Intolerable adverse effects 2
No reason given 1
a More than one treatment option could be chosen per participant. 
AET—adjuvant endocrine therapy; BCPT—Breast Cancer Prevention 
Trial
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were available and these often also have their own 
side effects. 
I feel like there isn’t any help really available. . . .
 You can take the suppository [estrogen containing 
for vaginal atrophy]. First thing the pharmacist 
says, “Well, I thought you weren’t supposed to be 
taking estrogen,” and I said, “Well, they told me I 
can take these.” 
I’m tired of taking [pills]. When someone says, 
“Take a pill for this [symptom],” I don’t want to 
start another pill. I think about all these other side 
effects. The lesser of two evils.
Theme	5:	Weighing	Pros	and	Cons	 
of	Ongoing	Treatment	
With the development of persistent and difficult-to-
manage symptoms, survivors begin to rethink their 
willingness to take AET and to weigh the pros and cons 
of ongoing treatment. Some women told the authors 
that they decided to continue AET and accept its related 
symptoms, whereas others reported that they were 
coming to the decision that the reduced risk of recur-
rence was not worth the loss of quality of life.
I’m going to take my medication, regardless. I 
mean I’m just going to take it. I’m convinced that 
taking it for five years with the other therapies that 
I’ve had increases my survival rate up to 10 years, 
but having talked to other women who have quit, 
they just really couldn’t get past the symptoms and 
I understand that.
Okay, I have a choice. I either continue this medi-
cine and know the side effects or I stop taking this 
medicine and know that there’s always a chance 
I’m going to get the cancer back. I think that’s what 
it is. You just know this medicine has side effects 
and you take it for what it’s worth.
Well, that was my big thing about taking [exemes-
tane]. If I have to take it for five years and my qual-
ity of life is so bad, do I want to take it? These are 
probably the last good five years of my life. I’m 60. 
Do I take it and have all these side effects?
You do get to a point where it just isn’t worth it to 
fight it [staying on AET]. 
Suggestions	for	Improving	Care	
Following the discussion of AET symptom experi-
ences, survivors were asked about ways the healthcare 
system could be improved to better meet their needs. 
Survivors said that they wished they had access to a 
knowledgeable source that would be able to provide 
more education about AET. 
What’ll help is taking the load off the oncologist, 
because their days are so busy. And when you 
know they’re dealing with people that are sick and 
going through treatment and we need someone to 
discuss these things now.
There has to be somebody helping us with those 
things. Why am I going off of [AET] in five years? 
We need a theory about what [anastrozole] is do-
ing to us. I worked in the medical field. I really 
don’t understand. It stops estrogen, okay, that’s all 
I know. I think that would really be helpful to help 
people understand why they’re taking it.
Things that would help with the side effects rather 
than waiting until you see the doctor six months 
later. You probably could have solved it within 
the first week starting therapy, or not had so much 
trouble with it, because nobody told me. 
Survivors were consistent in terms of what they 
needed; however, consensus about how best to get this 
support was not known. Various delivery options were 
mentioned, including printed materials, phone, synchro-
nous messaging, email, telemedicine, and face-to-face 
conversations. In terms of timing, some women said 
that they would prefer frequent, proactive interactions, 
whereas others preferred a less intense, more flexible 
support system that they could access themselves if or 
when desired. 
Email works for me, but it doesn’t work for ev-
erybody.
I’d rather just pick up the phone instead of like 
putting it all in an email. 
Survivors also indicated the need for more effective, 
affordable, and nonpharmacologic treatment options 
for AET-related symptoms. 
I just know it’s very frustrating though. When you 
have estrogen-positive tumors, that everything 
they recommend for these sleepless hot flashes are 
estrogen-based. It’s like, “Okay, well, what’s plan 
B? I can’t take that so what else can I do?” 
Insurance wouldn’t pay for a chiropractor. Insur-
ance doesn’t pay for physical therapy either.
Discussion
Results of this qualitative research study suggest that 
breast cancer survivors on AET encounter substantial 
challenges related to their experience and manage-
ment of AET-related symptoms. Initially, taking AET 
often was perceived as a nondecision, driven by their 
medical oncologist’s recommendation and fear of 
cancer recurrence. Women did not remember detailed 
discussions with their healthcare provider about the 
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potential adverse effects associated with AET. AET is 
the cornerstone treatment modality for women with 
hormone receptor–positive breast cancer to reduce 
their cancer recurrence risk (Burstein et al., 2010). To 
derive the most survival benefit, finding ways to sup-
port women to stay on therapy whenever possible 
is essential. Additional research is needed to explore 
whether experiences with AET reflected in the cur-
rent study were caused by insufficient education by 
providers and/or by survivor’s ability to participate 
in and remember this conversation. Findings would 
help prioritize the development of individualized 
educational interventions to improve AET adherence 
(Feldman-Stewart et al., 2013). Oncology nurses play a 
critical role in the development and implementation of 
these types of educational interventions. 
The type and nature of the AET-related symptoms 
discussed in the focus groups were consistent with 
previous clinical reports in the literature (Burstein et 
al., 2010; Hickey et al., 2008; Rechis et al., 2010; Stearns 
& Hayes, 2002; van Londen et al., 2013). However, the 
magnitude of bothersome symptoms was not always 
anticipated by patients, nor was the extent of interfer-
ence with sleep, activities of daily living, and function-
ing. The survivors, recruited at age 50 years and older, 
described great frustration with their difficulty in de-
termining the etiology of symptoms (i.e., AET, aging, 
and/or comorbidities). The women described receiving 
little understanding and support about symptoms from 
family and friends. Survivors expressed concerns that 
providers lacked time and expertise and gave them the 
feeling that experiencing AET-related symptoms was 
a sign of emotional weakness. This could contribute to 
a downward spiral of discouragement, worsening of 
symptoms, and AET discontinuation (Aiello Bowles et 
al., 2012; Cuijpers, Beekman, & Reynolds, 2012; Riegel 
et al., 2009) that can occur when experiencing chronic 
symptoms without adequate relief. These findings are 
consistent with Christensen’s (2000) Patient-by-Context 
Interaction Framework of Adherence. In this frame-
work, adherence is best understood as an interaction 
between a patient’s individual factors (e.g., personal 
traits, expectancies, coping processes) and illness/treat-
ment context factors (e.g., treatment controllability, ill-
ness severity). The framework has received attention as 
a useful way to examine the influence of symptoms on 
adherence to AET (Bender et al., 2014). Future research 
could further explore patient factors that are associated 
with increased risk for AET discontinuation as well as 
adaptive coping processes among women who persist 
on AET. These findings could assist researchers and 
clinicians in developing targeted interventions to pro-
mote adherence to AET. Educational, navigational, and 
behavioral interventions that target empowerment and 
improvement of self-care (Beekman, Smit, Stek, Reyn-
olds, & Cuijpers, 2010; Loh, Packer, Chinna, & Quek, 
2013; Wrosch & Sabiston, 2012) and are adaptable to 
survivors’ changing needs (Krebber et al., 2012) might 
be particularly beneficial. 
At some point, with persistent experiences of bother-
some AET-related symptoms, survivors reported grad-
ually beginning to recognize that they had a decision to 
make regarding whether they wanted to continue AET 
and accept the related symptoms, or discontinue AET 
prematurely and accept the potential for increased risk 
of recurrence. This has very important implications. 
These findings reflect serious unmet educational needs 
at the time of treatment initiation, namely that they may 
not fully understand the major risks of deciding to stop 
a treatment that is known to optimize survival in this 
patient population. Of note, all women in the current 
sample were on AET at the time of their participation 
in the focus group. However, this reflects the inclusion 
criteria requiring that women be on AET therapy for 
one year to be eligible to participate. This creates a 
sample of women who had decided to persist with AET. 
Literature has shown that about 17%–32% of initial 
AET users discontinue its intake within the first year 
(Henry et al., 2012; Partridge, Wang, Winer, & Avorn, 
2003), although some might tolerate alternative AET 
options (Henry et al., 2012). Future research should 
explore whether earlier, proactive, intermittent provi-
sion of education about the benefits and anticipated 
risks of AET as well as assessment and management of 
AET-related symptoms can improve survivors’ ability 
to persist with AET. 
Limitations
The study sample may affect the generalizability of 
the findings. Most of the survivors in the current study 
were Caucasian, married, and not employed and, there-
fore, may have had supportive resources not available 
to all survivors. This distribution does not represent all 
breast cancer survivors, as other ethnicities are under-
represented and most breast cancer survivors in their 
50s are employed (Rechis et al., 2010). The study group 
also focused on women taking AET for at least a year. 
Knowledge	Translation 
Adjuvant endocrine therapy (AET)–related symptoms are 
persistent and not always anticipated, contributing to a 
gradual reevaluation of the benefits and risks of AET. 
Oncology nurses must ensure that patients have adequate 
preparatory information regarding the potential risks and side 
effects as well as important benefits of AET. 
At AET initiation, oncology nurses should be proactive in 
monitoring and managing AET side effects.
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For these women, symptoms have not (yet, at least) led 
to early termination of therapy. However, the challeng-
es, as described in this article, might be even more pro-
nounced in those with less access to support and health 
care, as well as those who may have dropped out of 
treatment earlier. In addition, the authors did not find 
a difference between the self-report lymph node status 
groups. Although women may not have remembered 
their lymph node status, perhaps the structure of the 
focus group interviews did not specifically explore the 
relationship between lymph node status and perception 
of AET therapy. The authors also were unable to fully 
differentiate between symptoms related to AET versus 
chemotherapy. However, women were only eligible if 
they had been on AET for at least one year. In general, 
AET is not initiated until chemotherapy sessions have 
been completed. Therefore, women in the study were 
at least one year out from their last chemotherapy ses-
sion, which should have allowed for recovery from 
chemotherapy-related symptoms. 
Implications	for	Nursing
Oncology nurses have a responsibility to provide 
individualized education, not only at the time of AET 
initiation, but also over time. Key topics that may be 
particularly useful include information on (a) the fact 
that once breast cancer has reoccurred, it will likely not 
be curable anymore; however, the many different lines 
of therapy available might be able to provide long-term 
disease control and survival; (b) a woman’s individual 
risk of cancer recurrence; and (c) the expected reduc-
tion in risk associated with taking AET as prescribed 
(Burstein et al., 2010). Taking AET therapy consistently 
for five years can cut the breast cancer recurrence 
risk in about half; an additional five years of AET can 
result in an additional modest reduction. Another im-
portant topic for patient education by nurses includes 
an explanation of how the prescribed anti-estrogen 
agent works, why their cancer provider selected this 
particular agent (out of all the available anti-estrogen 
agents), and the possible adverse affects associated 
with the prescribed AET (Burstein et al., 2010). For 
example, estrogen receptor agonists/antagonists, such 
as tamoxifen, target the estrogen receptor, whereas 
the more effective aromatase inhibitors decrease the 
circulating levels of female gonadal hormones by in-
hibiting their peripheral production. Administration 
of aromatase inhibitors to premenopausal women is 
contraindicated as the ovaries might (over)compensate 
for the aromatase inhibitor-mediated decreased levels 
of female gonadal hormones. Therefore, if a woman 
should develop vaginal bleeding on an aromatase in-
hibitor, she should contact her prescribing provider, as 
it might be indicative of a resumption of ovarian func-
tion. An updated American Society of Clinical Oncol-
ogy guideline recommended that “addressing patient 
beliefs about the benefits and risks of medications is 
warranted in patient-provider interactions about the 
use of adjuvant endocrine therapy. Helping patients 
understand the rationale for therapy, and the likely 
adverse effects, is likely to enhance treatment compli-
ance and persistence” (Burstein et al., 2014).
This study also highlights the important role that 
nurses can play in the ongoing assessment and manage-
ment of AET-related symptoms. An explicit assessment 
of whether symptoms are affecting a woman’s willing-
ness or ability to persist with AET could help nurses 
to intervene early to prevent cessation of treatment. 
Specific strategies include the development of proac-
tive telephone follow-up protocols to evaluate the ef-
fectiveness of symptom management strategies, modify 
the approach if necessary, and reinforce the benefit of 
persisting with treatment. Referral to supportive care 
services should also be considered for women with 
persistent symptoms. 
Conclusions
The current study highlights the potential impact of 
AET-related symptom experience on survivors’ willing-
ness to continue on AET. Although women in this study 
were highly adherent despite unanticipated symptoms, 
their insights provide opportunities for patient- and 
provider-targeted interventions to improve AET-related 
symptom management, which could ultimately im-
prove AET adherence and survival. These findings may 
be instrumental in guiding the involvement of oncol-
ogy nurses in survivorship care to help women gain 
a more comprehensive understanding of the benefits 
and risks of AET (dis)continuation and feel supported 
in making informed decisions to maximize quality of 
life and survival.
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